A Phase 1/2 interventional study of Lenalidomide and Lenalidomide placebo in HIV-1 Infection, sponsored by Bionor Immuno AS. Completed at 4 sites in Germany. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-03-08.
Sponsored by Bionor Immuno AS · Phase 1/2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and ultimately immune deficiency. Vacc-4x is a peptide-based HIV immunotherapy and the primary objective is to strengthen the immune system's response to HIV p24. By adding Lenalidomide, an immunomodulatory agent, as a supporting drug, it is anticipated that the effect of Vacc-4x might be enhanced.
Human immunodeficiency virus (HIV) infects the CD4 subset of T-cells that are critical for initiating immune responses to infection. The level of CD4 cells in the blood is a marker of a patient's immunological status. The number of CD4 cells decreases in the course of the HIV infection and results in a reduced immunological response and eventually immune deficiency.
Vacc-4x is one of the few peptide-based therapeutic vaccines tested, and consists of four, slightly modified HIV Gag p24 consensus peptides. Vacc-4x was first tested by intradermal injections using GM-CSF as adjuvant. A recent multinational placebo-controlled study found improvement of vaccine-specific T cell immunity and decrease in viral loads (presented at the AIDS vaccine 2011 conference, Bangkok).
Lenalidomide (CC-5013) is a substance in the class of immunomodulatory agents. The lenalidomide mechanism of action includes anti-neoplastic, pro-erythropoietic, and immunomodulatory properties. Lenalidomide inhibits proliferation of certain hematopoietic tumor cells, enhances T cell- and Natural Killer (NK) cell-mediated immunity and increases the number of NK T cells.
The anti-HIV p24 immune response resulting from Vacc-4x immunization could in combination with ART potentially improve immune reconstitution in patients who have not fully regained a healthy CD4 level (> 600 x106/L). Adding the immunomodulatory agent Lenalidomide (CC-5013) to Vacc-4x immunization could enhance the immune response to Vacc-4x and further strengthen immune reconstitution.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 36 is below the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →Bionor Immuno AS is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patient receive intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide in a dose escalation (3+3) design. Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is non tolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013)
Drug: Lenalidomide · Drug: Vacc-4X · Drug: rhuGM-CSF
Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) \& lenalidomide (dose determined in Part A) two days prior to and at the day of immunization.
Drug: Lenalidomide · Drug: Vacc-4X · Drug: rhuGM-CSF
Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) \& lenalidomide placebo two days prior to and at the day of immunization.
Drug: Lenalidomide placebo · Drug: Vacc-4X · Drug: rhuGM-CSF
In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
Also known as: Lenalidomide capsule
Capsules are identical to the active Lenalidomide capsules used.
Also known as: placebo
Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
Also known as: Combination of Vacc-10, Vacc-11, Vacc-12 and Vacc-13.
Granulocyte macrophage colony stimulating factor as a local adjuvant
Also known as: Leukine®
Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity
Number of participants in each of the three groups that experienced any dose-limiting toxicity.
Time frame: 31 days
Part A: To Establish Highest Tolerated Dose of Lenalidomide, CD4 Counts Over Time
Time frame: 31 days
Part B: Change in CD4 Count
Change in CD4 count from baseline to Week 26.
Time frame: Week 26
Part B: Change in CD8 Count
Change in CD8 count from baseline to week 26.
Time frame: 26 weeks
Part B: Evaluate the Effect on HIV Viral Load
Results BLQ (\<20 HIV copies/mL) have been replaced with BLQ/2 = 10 HIV copies/mL while 'not detected' results have been replaced with 0 HIV copies/mL.
Time frame: 26 weeks
Part B: Incidents of Delayed-type Hypersensitivity
Delayed-type hypersensitivity measured by induration and erythema.
Time frame: 26 weeks
Part A and B: Safety and Tolerability
Time frame: Part A: 31 days and Part B: 26 weeks
| Milestone | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg | Part B: Lenalidomide | Part B: Lenalidomide Placebo |
|---|---|---|---|---|---|
| Started | 3 | 3 | 6 | 12 | 12 |
| Completed | 3 | 3 | 6 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Number of participants in each of the three groups that experienced any dose-limiting toxicity.
| Participants | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg |
|---|---|---|---|
| Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity | 0 | 0 | 0 |
| 10^6 cells/mL | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg |
|---|---|---|---|
| Baseline | 437.3 ± 38.30 | 436.3 ± 60.05 | 454.2 ± 86.59 |
| Week 1 | 393.0 ± 167.56 | 317.0 ± 18.52 | 342.2 ± 27.13 |
| Week 4 | 442.0 ± 121.77 | 399.3 ± 15.95 | 450.7 ± 147.02 |
| Week 5 | 432.7 ± 242.47 | 449.0 ± 71.04 | 452.3 ± 66.28 |
Change in CD4 count from baseline to Week 26.
| 10^6 cells/L | Part B: Lenalidomide | Part B: Lenalidomide Placebo |
|---|---|---|
| ITT | 90.9 ± 98.79 | 42.2 ± 81.40 |
| PP | 106.3 ± 101.00 | 49.1 ± 81.58 |
Change in CD8 count from baseline to week 26.
| 10^6 cells/L | Part B: Lenalidomide | Part B: Lenalidomide Placebo |
|---|---|---|
| Baseline | 734.2 ± 473.14 | 655.3 ± 325.19 |
| Week 1 | 653.8 ± 382.16 | 784.5 ± 372.96 |
| Week 4 | 744.9 ± 485.49 | 794.5 ± 452.91 |
| Week 12 | 823.0 ± 548.84 | 760.3 ± 432.79 |
| Week 13 | 811.2 ± 557.52 | 663.6 ± 393.95 |
Results BLQ (\<20 HIV copies/mL) have been replaced with BLQ/2 = 10 HIV copies/mL while 'not detected' results have been replaced with 0 HIV copies/mL.
| Copies/mL | Part B: Lenalidomide | Part B: Lenalidomide Placebo |
|---|---|---|
| Baseline | 0.8 ± 2.89 | 2.5 ± 4.52 |
| Week 1 | 5.1 ± 9.30 | 0.0 ± 0.00 |
| Week 4 | 6.4 ± 8.17 | 0.9 ± 3.02 |
| Week 12 | 5.5 ± 11.29 | 4.3 ± 6.90 |
| Week 13 | 7.4 ± 19.77 | 1.7 ± 3.89 |
| Week 21 | 1.7 ± 3.89 | 4.2 ± 5.15 |
| Week 26 | 3.5 ± 6.99 | 2.5 ± 4.52 |
Delayed-type hypersensitivity measured by induration and erythema.
| Participants | Part B: Lenalidomide | Part B: Lenalidomide Placebo |
|---|---|---|
| Week 1, Induration | 0 | 0 |
| Week 1, Erythema | 0 | 1 |
| Week 26, Induration | 5 | 2 |
| Week 26, Erythema | 6 | 6 |
| participants | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg | Part B: Lenalidomide | Part B: Lenalidomide Placebo |
|---|---|---|---|---|---|
| With any TEAE | 3 | 2 | 6 | 10 | 9 |
| With TESAE | 0 | 0 | 0 | 1 | 0 |
| With any AE resultiung in withdrawal | 0 | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 | 0 |
Collected over Adverse events were collected from the time of signing informed consent and until last visit; 31 days in Part A and 26 weeks in Part B. In addition, a 5-year survival follow-up period during which telephone contact from site for all subjects who discontinue treatment at any time will be conducted every 4 months for the first two years and every 6 months thereafter for a minimum of 5 years post-inclusion for survival, cause(s) of death, disease progression and post-treatment therapy(ies).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Lenalidomide 5 mg | — | 0/3 (0%) | 3/3 (100%) |
| Part A: Lenalidomide 10 mg | — | 0/3 (0%) | 2/3 (66.7%) |
| Part A: Lenalidopmide 25 mg | — | 0/6 (0%) | 6/6 (100%) |
| Part B: Lenalidomide | — | 1/12 (8.3%) | 10/12 (83.3%) |
| Part B: Lenalidomide Placebo | — | 0/12 (0%) | 9/12 (75%) |
| Event | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg | Part B: Lenalidomide | Part B: Lenalidomide Placebo |
|---|---|---|---|---|---|
| Abscess left upper armInfections and infestations | 0/3 | 0/3 | 0/6 | 1/12 | 0/12 |
| Event | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg | Part B: Lenalidomide | Part B: Lenalidomide Placebo |
|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 2/3 | 1/3 | 2/6 | 4/12 | 2/12 |
| Injection site pruritusGeneral disorders | 2/3 | 0/3 | 1/6 | 3/12 | 2/12 |
| FatigueGeneral disorders | 1/3 | 0/3 | 1/6 | 2/12 | 4/12 |
| Injection site swellingGeneral disorders | 1/3 | 1/3 | 0/6 | 2/12 | 0/12 |
| Injection site indurationGeneral disorders | 1/3 | 0/3 | 0/6 | 1/12 | 0/12 |
| Injection site painGeneral disorders | 1/3 | 0/3 | 0/6 | 1/12 | 2/12 |
| Injection site warmthGeneral disorders | 1/3 | 0/3 | 0/6 | 0/12 | 0/12 |
| Tooth infectionInfections and infestations | 0/3 | 1/3 | 0/6 | 0/12 | 1/12 |
| SunisitisInfections and infestations | 0/3 | 1/3 | 0/6 | 0/12 | 0/12 |
| PruritusSkin and subcutaneous tissue disorders | 0/3 | 0/3 | 2/6 | 3/12 | 0/12 |
| Age, Continuous(years) | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg | Part B: Lenalidomide | Part B: Lenalidomide Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 43.7 ± 4.16 | 35.7 ± 3.06 | 46.2 ± 5.42 | 44.4 ± 7.97 | 41.5 ± 8.04 | 42.9 ± 7.34 |
| Gender(Participants) | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg | Part B: Lenalidomide | Part B: Lenalidomide Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 3 | 3 | 6 | 12 | 12 | 36 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg | Part B: Lenalidomide | Part B: Lenalidomide Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 3 | 6 | 12 | 12 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg | Part B: Lenalidomide | Part B: Lenalidomide Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 0 | 1 |
| White | 3 | 1 | 6 | 12 | 11 | 33 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| BMI(kg/m^2) | Part A: Lenalidomide 5 mg | Part A: Lenalidomide 10 mg | Part A: Lenalidopmide 25 mg | Part B: Lenalidomide | Part B: Lenalidomide Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 23.7 ± 2.32 | 27.9 ± 7.65 | 24.4 ± 1.75 | 23.6 ± 3.85 | 23.5 ± 3.44 | 24.1 ± 3.74 |
Plan to share: No — Participants have not provided informed consent for their anonymized individual data to be made available beyond that described in the patient information sheet.
The record gives a start of Sep 2012, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide
Bionor Immuno AS